证券代码：688192 证券简称：迪哲医药 公告编号：2025-41 迪哲（江苏）医药股份有限公司 关于高级管理人员减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 1 持前所持有公司股份数量均不超过 25%。减持期间自 2025 年 7 月 18 日至 2025 年 10 月 17 日，减持价格将按照减持实施期间的市场价格确定。 | 股东名称 | 陈素勤 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | □是 | √否 | | | 董事、监事和高级管理人员 | √是 | □否 | | | 其他：无 | | | | 持股数量 | 519,500股 | | | | 持股比例 | 0.1131% | | | | 当前持股股份来源 | 股权激励取得：519,500股 | | | | 股东名称 | Qingbei Zeng | | | --- | --- | --- ...

Core Viewpoint - The announcement details the upcoming listing and circulation of restricted shares for Dize Pharmaceutical Co., Ltd., with a total of 223,013,329 shares set to be released on July 1, 2025, representing 48.54% of the company's total share capital [1][3][13]. Summary by Sections Listing of Restricted Shares - The type of shares being listed is restricted shares from the company's initial public offering (IPO) [2]. - The total number of shares to be listed is 223,013,329, which will be available for trading starting July 1, 2025 [1][6]. Shareholder Commitments - Major shareholders, including Advanced Manufacturing Industry Investment Fund and AstraZeneca AB, are required to adhere to specific commitments regarding share lock-up and reduction [2][3]. - The first major shareholder, Advanced Manufacturing, and AstraZeneca AB are prohibited from reducing their holdings through trading until certain conditions are met, particularly if the company has not paid cash dividends due to losses [2][3]. Changes in Share Capital - The company's total share capital has increased from 400,000,100 shares to 459,412,894 shares due to various stock option plans and incentive programs [4][5]. - The increase includes 12,103,020 shares from the 2020 employee stock option plan and additional shares from the 2022 restricted stock incentive plan [4][5]. Commitments from Major Shareholders - Advanced Manufacturing and AstraZeneca AB have committed not to transfer or manage their shares for 36 months following the company's IPO [8][10]. - If the company does not achieve profitability, these shareholders cannot reduce their holdings for three full accounting years after the IPO [8][10]. Verification by Intermediaries - The underwriting institution, Huatai United Securities, has confirmed that all commitments related to the restricted shares have been strictly adhered to by the shareholders [11]. - The verification indicates that the listing of restricted shares complies with relevant laws and regulations [11]. Details of Restricted Shares - The total number of restricted shares being listed is 223,013,329, which will be available for trading on July 1, 2025 [6][13]. - The shareholders holding these restricted shares include Advanced Manufacturing, AstraZeneca AB, and ZYTZ Partners Limited [3][13].

华泰联合证券有限责任公司关于 迪哲（江苏）医药股份有限公司 首次公开发行部分限售股上市流通的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"、"保荐机构"）作为迪哲 （江苏）医药股份有限公司（以下简称"迪哲医药"或"公司"）2023 年度向特定对 象发行 A 股股票的保荐机构，根据《证券发行上市保荐业务管理办法》 《科创板 上市公司持续监管办法（试行）》《上海证券交易所科创板股票上市规则》《上海 证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关规定履行 持续督导职责，对迪哲医药首次公开发行部分限售股上市流通的相关情况进行了 审慎核查，核查情况如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2021 年 11 月 3 日出具的《关于同意迪哲 （江 | | 股份变动事项 | | 公告索引 | | | --- | --- | --- | --- | --- | | 号 间 | 权新增的股份完成登记 | 量（股） | | （公告编号：2021-006） | | | | | 动的公告》 | | | | 一次行权新增的股份完 | | | 股份变动的公告》（公告编 | | 号： ...

Meeting Overview - The shareholders' meeting of Dize Pharmaceutical (Jiangsu) Co., Ltd. was held on June 23, 2025, in Wuxi City, Xinwu District [1] - A total of 99 ordinary shareholders attended the meeting, holding 295,711,183 voting rights, which accounts for 64.3671% of the company's total voting rights [1] Voting Results - All proposed resolutions were approved during the meeting [2][3] - The voting results showed that for the first resolution, 295,693,167 votes (99.9939%) were in favor, with only 4,600 votes against [2] - Subsequent resolutions also received overwhelming support, with approval rates consistently above 99.98% [2][3] Legal Compliance - The meeting was conducted in accordance with the Company Law and the company's articles of association, with the presence of qualified attendees and proper voting procedures [3][4] - Legal opinions were provided by lawyers Wang Yuan and Chen Tong, confirming the legality of the meeting and its resolutions [3]

Core Points - The legal opinion letter confirms the legality of the 2024 annual general meeting of Dize (Jiangsu) Pharmaceutical Co., Ltd. [1][16] - The opinion is based on the review of relevant laws, regulations, and the company's articles of association [1][2] Group 1: Meeting Procedures - The notice for the 2024 annual general meeting was properly communicated to all shareholders, including details on time, location, and agenda [3][4] - The meeting was convened in accordance with the relevant legal and regulatory requirements [4][15] Group 2: Attendance and Qualifications - A total of 9 shareholders and their proxies attended the meeting, representing 178,558,990 shares, which is 38.87% of the total voting shares [4][6] - The qualifications of the attendees were verified, confirming their legitimacy to participate in the meeting [4][6] Group 3: Voting Procedures and Results - Voting was conducted through both on-site and online methods, with results being monitored and counted by designated personnel [6][15] - The voting results showed that 295,693,967 shares were in favor of the proposals, representing a significant majority of the votes cast [7][14]

证券代码：688192 证券简称：迪哲医药 公告编号：2025-39 迪哲（江苏）医药股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 223,013,329股。 本次股票上市流通总数为223,013,329股。 本次股票上市流通日期为2025 年 7 月 1 日。 相关股东除遵守作出的关于所持迪哲（江苏）医药股份有限公司（以下简称 "公司"或"迪哲医药"）股份锁定、减持相关承诺外，还需遵守《上市公司股 东减持股份管理暂行办法》《上海证券交易所上市公司自律监管指引第 15 号—— 股东及董事、高级管理人员减持股份》等法规及规范性文件中关于股份减持的相 关规定。根据前述规定，截至本公告出具日，在公司最近三个已披露经审计的年 度报告的会计年度因亏损而未进行现金分红的情况下，第一大股东先进制造产业 投资基金（有限合伙）（以下简称"先进制造"）和 AstraZeneca AB （以下简称 "AZAB"）不 ...

华泰联合证券有限责任公司关于 迪哲（江苏）医药股份有限公司 首次公开发行部分限售股上市流通的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"、"保荐机构"）作为迪哲 （江苏）医药股份有限公司（以下简称"迪哲医药"或"公司"）2023 年度向特定对 象发行 A 股股票的保荐机构，根据《证券发行上市保荐业务管理办法》《科创板 上市公司持续监管办法（试行）》《上海证券交易所科创板股票上市规则》《上海 证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关规定履行 持续督导职责，对迪哲医药首次公开发行部分限售股上市流通的相关情况进行了 审慎核查，核查情况如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2021 年 11 月 3 日出具的《关于同意迪哲（江 苏）医药股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕3494 号），公司首次向社会公开发行人民币普通股（A 股）40,000,100 股，并于 2021 年 12 月 10 日在上海证券交易所科创板上市。发行完成后公司总股本为 400,000,100 股，其中有限售条件流通股 363,050,516 股，无限 ...

迪哲（江苏）医药股份有限公司 2024年年度股东大会决议公告 证券代码：688192 证券简称：迪哲医药 公告编号：2025-40 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 6 月 23 日 （二） 股东大会召开的地点：无锡市新吴区新阳路 50 号 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 99 | | --- | --- | | 普通股股东人数 | 99 | | 2、出席会议的股东所持有的表决权数量 | 295,711,183 | | 普通股股东所持有表决权数量 | 295,711,183 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 64.3671 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 64.3671 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持 ...

北京市中伦律师事务所 关于迪哲（江苏）医药股份有限公司 北京市中伦律师事务所 关于迪哲（江苏）医药股份有限公司 2024 年年度股东大会的 法律意见书 二〇二五年六月 2024 年年度股东大会的 法律意见书 致：迪哲（江苏）医药股份有限公司 根据迪哲（江苏）医药股份有限公司（以下简称"公司"）与北京市中伦律 师事务所（以下简称"本所"）签订的《常年法律服务协议》的约定及受本所指 派，本所律师对公司 2024 年年度股东大会（以下简称"本次股东大会"）的合 法性进行见证并出具法律意见。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委 员会（以下简称"中国证监会"）《上市公司股东会规则》（以下简称"《股东 会规则》"）等现行有效的有关法律、法规和规范性文件以及《迪哲（江苏）医 药股份有限公司章程》（以下简称"《公司章程》"）的规定而出具。 为出具本法律意见书，本所律师审查了公司本次股东大会的有关文件和材料。 本所律师得到公司如下保证，即其已提供了本所律师认为出具本法律意见书所必 需的材料，所提供的原始材料、副本、复印件等 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical industry, indicating a positive outlook for the sector compared to the overall market performance [23]. Core Insights - The pharmaceutical sector experienced a decline of 4.4% this week, underperforming the Shanghai Composite Index, which fell by 0.5% [2][3]. - The overall valuation of the pharmaceutical sector stands at 28.7 times PE (2025E), ranking it 5th among 31 sub-industries [5][10]. - Recent policies from the National Medical Products Administration (NMPA) aim to support the development of high-end medical devices and accelerate the clinical review process for innovative drugs [12]. - Shengnuo Biopharma forecasts a significant profit increase for H1 2025, with expected net profit ranging from 77.03 million to 94.14 million yuan, marking a year-on-year growth of 253.54% to 332.10% [13]. Market Performance - The pharmaceutical and biotechnology index ranked 29th out of 31 sub-industries this week, with various segments showing declines, including chemical preparations (-5.7%) and medical devices (-3.7%) [2][5]. - The report highlights the strong growth in product revenue and licensing deals in the innovative drug sector over the past three years, with a focus on companies expected to release major products and those involved in the CXO industry [12]. Key Events - The NMPA has approved measures to encourage the innovation of high-end medical devices, including optimizing special approval processes and enhancing regulatory frameworks [12]. - The NMPA has also proposed a 30-day review process for clinical trial applications of innovative drugs, aimed at improving the efficiency of drug development [12].